Now, the German company has issued a reminder of its original R&D mission with the start of the first phase 2 trial of BNT111 – the first of several cancer vaccine candidates – in patients with skin cancer.
Pre-pandemic, the plan was to start both a phase 2 and phase 3 of BNT111 in 2020, but with the Pfizer-partnered COVID-19 shot consuming its attention, timelines have slipped back.
The phase 2 study is testing BNT111 in combination with Regeneron/Sanofi’s PD-1 inhibitor Libtayo (cemiplimab) in patients with advanced melanoma who have relapsed after or not responded to treatment with a PD-1/PD-L1 inhibitor drug.
